Advanced Search
    WANG Sheng-zao, WANG Hua-jun, CHEN Hong-ming, YUE Yu, BU Fan-jin, ZHANG Xue-mei. Lianhua Qingwen capsule and interferon-α combined with lopinavir/ritonavir for the treatment of 30 COVID-19 patients[J]. Journal of Bengbu Medical University, 2020, 45(2): 154-155. DOI: 10.13898/j.cnki.issn.1000-2200.2020.02.004
    Citation: WANG Sheng-zao, WANG Hua-jun, CHEN Hong-ming, YUE Yu, BU Fan-jin, ZHANG Xue-mei. Lianhua Qingwen capsule and interferon-α combined with lopinavir/ritonavir for the treatment of 30 COVID-19 patients[J]. Journal of Bengbu Medical University, 2020, 45(2): 154-155. DOI: 10.13898/j.cnki.issn.1000-2200.2020.02.004
    shu

    Lianhua Qingwen capsule and interferon-α combined with lopinavir/ritonavir for the treatment of 30 COVID-19 patients

      Graphical Abstract
      • Abstract
    • ObjectiveTo investigate the efficacy of lopinavir/ritonavir for the treatment of corona virus disease 2019 (COVID-19).
      MethodsA total of 60 patients with COVID-19 were divided into two groups (30 cases in each group).The control group was treated with Lianhua Qingwen capsule and interferon-α, and the observation group was treated with lopinavir/ritonavir on the basis of control group.The therapeutic efficacy of two groups was compared.
      ResultsIn observation group, 13 cases were with notable therapeutic efficacy, and 10 cases with partially effective efficacy; in control group, 3 cases were with notable therapeutic efficacy, and 11 cases with partially effective efficacy.The effective rate of treatment in observation group (76.67%) was significantly higher than that in control group (46.67%) (P < 0.01).
      ConclusionsLopinavir/ritonavir is effective for the treatment of COVID-19.
      • FullText(HTML)
    • loading
      • References (6)
      • Related Articles
    • Supplements (0)

    Catalog

      Turn off MathJax
      Article Contents

      /

      DownLoad:  Full-Size Img  PowerPoint
      Return
      Return